Barbara Burtness
芭芭拉·伯特尼斯
MD
Professor of Medicine (Medical Oncology); Co-Leader, Developmental Therapeutics Program, Yale Cancer Center医学（肿瘤内科）教授，耶鲁癌症中心发展治疗学项目联合主任
👥Biography 个人简介
Barbara Burtness, MD is Professor of Medicine (Medical Oncology) and Co-Leader of the Developmental Therapeutics Program at Yale Cancer Center. She is one of the leading clinical investigators in head and neck oncology in the United States, recognized particularly as co-principal investigator of KEYNOTE-048—the landmark trial that established pembrolizumab as the new first-line standard for recurrent/metastatic HNSCC. Dr. Burtness has conducted foundational clinical research on EGFR-targeted therapy in HNSCC, including an early landmark Eastern Cooperative Oncology Group (ECOG) trial demonstrating that cetuximab improves outcomes when added to cisplatin in recurrent/metastatic HNSCC, one of the first positive randomized trials in this population. She has been a leader in cooperative group HNSCC trials through ECOG-ACRIN and has designed studies examining EGFR inhibition, immunotherapy combinations, and novel targeted approaches. Dr. Burtness is known for her contributions to the understanding of HNSCC biology, treatment toxicity management (particularly dermatologic toxicity from EGFR inhibitors), and her commitment to mentoring the next generation of head and neck oncologists.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
KEYNOTE-048 Co-Principal Investigator
Served as co-PI of KEYNOTE-048, the phase III trial demonstrating pembrolizumab monotherapy (PD-L1 CPS ≥1) and pembrolizumab plus chemotherapy are superior to the EXTREME regimen in first-line recurrent/metastatic HNSCC, earning FDA approval and reshaping the global standard of care.
Cetuximab Plus Cisplatin in R/M HNSCC — ECOG Trial
Led the pivotal ECOG 5397 randomized trial demonstrating that adding cetuximab to cisplatin in recurrent/metastatic HNSCC significantly improved overall response rate, providing early evidence of EGFR-targeted therapy benefit and informing the rationale for the EXTREME regimen.
EGFR Inhibitor Toxicity Management
Developed expert consensus guidance and clinical best-practices for management of EGFR inhibitor-associated dermatologic toxicities in HNSCC, including acneiform rash, paronychia, and xerosis, improving patient quality of life and treatment adherence.
Cooperative Group HNSCC Trial Leadership
Served in ECOG-ACRIN leadership for head and neck cancer, designing and executing cooperative group trials that have enrolled hundreds of HNSCC patients and generated critical evidence for standard-of-care updates across disease settings.
Representative Works 代表性著作
Phase III Randomized Trial of Cisplatin plus Placebo Compared with Cisplatin plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study
Journal of Clinical Oncology (2005)
ECOG 5397 randomized trial demonstrating improved response rate for cetuximab plus cisplatin versus cisplatin alone in R/M HNSCC, an early foundation for EGFR-targeted therapy in this disease.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048)
The Lancet (2019)
Co-authored pivotal KEYNOTE-048 trial establishing pembrolizumab ± chemotherapy as new first-line standard of care in R/M HNSCC.
Management of Dermatologic Toxicities Associated with Epidermal Growth Factor Receptor Inhibition
Journal of Supportive Oncology (2009)
Expert guidance on identification, grading, and management of EGFR inhibitor skin toxicities in patients with HNSCC and other solid tumors.
Targeting the EGFR Family in Squamous Cell Carcinoma of the Head and Neck
Frontiers in Oncology (2015)
Comprehensive review of EGFR family biology and targeting strategies in HNSCC with analysis of predictive biomarkers and resistance mechanisms.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 芭芭拉·伯特尼斯 的研究动态
Follow Barbara Burtness's research updates
留下邮箱，当我们发布与 Barbara Burtness（Yale School of Medicine / Yale Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment